Expert opinion on drug metabolism & toxicology最新文献_第9页

Interactions between grapefruit juice and psychotropic medications: an update of the literature and an original case series. 葡萄柚汁与精神药物之间的相互作用：文献更新和原始病例系列。

Expert opinion on drug metabolism & toxicology Pub Date : 2024-05-01 Epub Date: 2024-05-09 DOI: 10.1080/17425255.2024.2352468

Marcin Siwek, Anna Julia Krupa, Jarosław Woroń

{"title":"Interactions between grapefruit juice and psychotropic medications: an update of the literature and an original case series.","authors":"Marcin Siwek, Anna Julia Krupa, Jarosław Woroń","doi":"10.1080/17425255.2024.2352468","DOIUrl":"10.1080/17425255.2024.2352468","url":null,"abstract":"Introduction: There is a large body of preclinical data implicating that grapefruit juice (GJ) inhibits many CYP 450 isoforms. The potential of GJ-to-drug is of high relevance to clinical psychiatry, because a wide range of psychotropic medicines undergo CYP 450 metabolism and P-gp transport.Areas covered: Relevant data were identified by searching the electronic databases up to February 2024. This work constitutes a summary of preclinical and clinical data on GJ impact on CYP 450 metabolism, P-glycoprotein, and organic anion-transporting polypeptides (OATPs), with focus on studies that assessed GJ-to-psychotropic drug interactions. Additionally, an unpublished case series of nine patients is provided.Expert opinion: The impact of GJ on CYP 3A4 appears to be the critical mechanism for the majority of GJ-to-psychopharmacotherapy interactions described in human studies or case reports. However, there are studies and cases of patients clearly showing that this is not the only route explaining the GJ effect, and at times, this particular is of no relevance and that other CYP 450 isoforms as well as drug transporting proteins might be involved. The risk of GJ-to-psychotropic drugs needs to be further evaluated in a 'real-world' setting and apply not only measures of pharmacokinetics but also treatment effectiveness and safety.","PeriodicalId":94005,"journal":{"name":"Expert opinion on drug metabolism & toxicology","volume":" ","pages":"333-345"},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140893080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluating the pharmacokinetics of upadacitinib for the treatment of moderate-to-severe Crohn's disease. 评估奥达帕替尼治疗中重度克罗恩病的药代动力学。

Expert opinion on drug metabolism & toxicology Pub Date : 2024-05-01 Epub Date: 2024-05-13 DOI: 10.1080/17425255.2024.2349711

Ilaria Faggiani, Ferdinando D'Amico, Francesca Bernardi, Sarah Bencardino, Mariangela Allocca, Federica Furfaro, Tommaso Lorenzo Parigi, Alessandra Zilli, Gionata Fiorino, Laurent Peyrin-Biroulet, Silvio Danese

{"title":"Evaluating the pharmacokinetics of upadacitinib for the treatment of moderate-to-severe Crohn's disease.","authors":"Ilaria Faggiani, Ferdinando D'Amico, Francesca Bernardi, Sarah Bencardino, Mariangela Allocca, Federica Furfaro, Tommaso Lorenzo Parigi, Alessandra Zilli, Gionata Fiorino, Laurent Peyrin-Biroulet, Silvio Danese","doi":"10.1080/17425255.2024.2349711","DOIUrl":"10.1080/17425255.2024.2349711","url":null,"abstract":"Introduction: Janus kinases (JAK) are enzymes involved in signaling pathways that activate the immune system. Upadacitinib, an oral small molecule, is the first JAK inhibitor approved by FDA and EMA for the treatment of moderately to severely active Crohn's disease (CD), following successful phase II and III trials. Compared to other JAK inhibitors, upadacitinib has a high selectivity toward JAK1. This characteristic could improve its efficacy and safety.Areas covered: This review provides an overview of the available knowledge on the pharmacokinetics of upadacitinib as induction and maintenance therapy for CD.Expert opinion: The approval of newer targeted small molecules drug, including JAK inhibitors, marked a significant advancement in terms of effectiveness. In fact, the oral administration, the rapid absorption, the excellent bioavailability and the short serum time of maximum concentration are some of the advantages compared to biologics. The selective inhibition of JAK1 by upadacitinib allows for high efficacy while maintaining a reliable safety profile.","PeriodicalId":94005,"journal":{"name":"Expert opinion on drug metabolism & toxicology","volume":" ","pages":"297-305"},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140854860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Interactions between antiepileptic drugs and direct oral anticoagulants for primary and secondary stroke prevention. 抗癫痫药物与直接口服抗凝剂在中风一级和二级预防中的相互作用。

Expert opinion on drug metabolism & toxicology Pub Date : 2024-05-01 Epub Date: 2024-05-09 DOI: 10.1080/17425255.2024.2352466

Claudia Stöllberger, Josef Finsterer, Birke Schneider

{"title":"Interactions between antiepileptic drugs and direct oral anticoagulants for primary and secondary stroke prevention.","authors":"Claudia Stöllberger, Josef Finsterer, Birke Schneider","doi":"10.1080/17425255.2024.2352466","DOIUrl":"10.1080/17425255.2024.2352466","url":null,"abstract":"Introduction: Direct oral anticoagulants (DOAC) are the guideline-recommended therapy for prevention of stroke in atrial fibrillation (AF) and venous thromboembolism. Since approximately 10% of patients using antiepileptic drugs (AED) also receive DOAC, aim of this review is to summarize data about drug-drug interactions (DDI) of DOAC with AED by using data from PubMed until December 2023.Areas covered: Of 49 AED, only 16 have been investigated regarding DDI with DOAC by case reports or observational studies. No increased risk for stroke was reported only for topiramate, zonisamide, pregabalin, and gabapentin, whereas for the remaining 12 AED conflicting results regarding the risk for stroke and bleeding were found. Further 16 AED have the potential for pharmacodynamic or pharmacokinetic DDI, but no data regarding DOAC are available. For the remaining 17 AED it is unknown if they have DDI with DOAC.Expert opinion: Knowledge about pharmacokinetic and pharmacodynamic DDI of AED and DOAC is limited and frequently restricted to in vitro and in vivo findings. Since no data about DDI with DOAC are available for 67% of AED and an increasing number of patients have a combined medication of DOAC and AED, there is an urgent need for research on this topic.","PeriodicalId":94005,"journal":{"name":"Expert opinion on drug metabolism & toxicology","volume":" ","pages":"359-376"},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140873862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Contribution of aldehyde oxidase to methotrexate-induced hepatotoxicity: in vitro and pharmacoepidemiological approaches. 醛氧化酶对甲氨蝶呤诱导的肝毒性的贡献：体外和药物流行病学方法。

Expert opinion on drug metabolism & toxicology Pub Date : 2024-05-01 Epub Date: 2024-05-09 DOI: 10.1080/17425255.2024.2352453

Ayako Moriyama, Hinata Ueda, Katsuya Narumi, Shuho Asano, Ayako Furugen, Yoshitaka Saito, Masaki Kobayashi

{"title":"Contribution of aldehyde oxidase to methotrexate-induced hepatotoxicity: in vitro and pharmacoepidemiological approaches.","authors":"Ayako Moriyama, Hinata Ueda, Katsuya Narumi, Shuho Asano, Ayako Furugen, Yoshitaka Saito, Masaki Kobayashi","doi":"10.1080/17425255.2024.2352453","DOIUrl":"10.1080/17425255.2024.2352453","url":null,"abstract":"Background: Methotrexate (MTX) is partially metabolized by aldehyde oxidase (AOX) in the liver and its clinical impact remains unclear. In this study, we aimed to demonstrate how AOX contributes to MTX-induced hepatotoxicity in vitro and clarify the relationship between concomitant AOX inhibitor use and MTX-associated liver injury development using the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS).Methods: We assessed intracellular MTX accumulation and cytotoxicity using HepG2 cells. We used the FAERS database to detect reporting odds ratio (ROR)-based MTX-related hepatotoxicity event signals.Results: AOX inhibition by AOX inhibitor raloxifene and siRNA increased the MTX accumulation in HepG2 cells and enhanced the MTX-induced cell viability reduction. In the FAERS analysis, the ROR for MTX-related hepatotoxicity increased with non-overlap of 95% confidence interval when co-administered with drugs with higher Imax, u (maximum unbound plasma concentration)/IC50 (half-maximal inhibitory concentration for inhibition of AOX) calculated based on reported pharmacokinetic data.Conclusion: AOX inhibition contributed to MTX accumulation in the liver, resulting in increased hepatotoxicity. Our study raises concerns regarding MTX-related hepatotoxicity when co-administered with drugs that possibly inhibit AOX activity at clinical concentrations.","PeriodicalId":94005,"journal":{"name":"Expert opinion on drug metabolism & toxicology","volume":" ","pages":"399-406"},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140861398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pharmacogenetics in IBS: update and impact of GWAS studies in drug targets and metabolism. 肠易激综合征的药物遗传学：药物靶点和代谢 GWAS 研究的更新和影响。

Expert opinion on drug metabolism & toxicology Pub Date : 2024-05-01 Epub Date: 2024-05-26 DOI: 10.1080/17425255.2024.2349716

Michael Camilleri, Kara Jencks

{"title":"Pharmacogenetics in IBS: update and impact of GWAS studies in drug targets and metabolism.","authors":"Michael Camilleri, Kara Jencks","doi":"10.1080/17425255.2024.2349716","DOIUrl":"10.1080/17425255.2024.2349716","url":null,"abstract":"Introduction: Medications are frequently prescribed for patients with irritable bowel syndrome (IBS) or disorders of gut brain interaction. The level of drug metabolism and modifications in drug targets determine medication efficacy to modify motor or sensory function as well as patient response outcomes.Areas covered: The literature search included PubMed searches with the terms: pharmacokinetics, pharmacogenomics, epigenetics, clinical trials, irritable bowel syndrome, disorders of gut brain interaction, and genome-wide association studies. The main topics covered in relation to irritable bowel syndrome were precision medicine, pharmacogenomics related to drug metabolism, pharmacogenomics related to mechanistic targets, and epigenetics.Expert opinion: Pharmacogenomics impacting drug metabolism [CYP 2D6 (cytochrome P450 2D6) or 2C19 (cytochrome P450 2C19)] is the most practical approach to precision medicine in the treatment of IBS. Although there are proof of concept studies that have documented the importance of genetic modification of transmitters or receptors in altering responses to medications in IBS, these principles have rarely been applied in patient response outcomes. Genome-wide association (GWAS) studies have now documented the association of symptoms with genetic variation but not the evaluation of treatment responses. Considerably more research, particularly focused on patient response outcomes and epigenetics, is essential to impact this field in clinical medicine.","PeriodicalId":94005,"journal":{"name":"Expert opinion on drug metabolism & toxicology","volume":" ","pages":"319-332"},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11139426/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141086321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pharmacokinetic considerations for drugs that treat diarrhea-predominant irritable bowel syndrome: what's new? 治疗以腹泻为主的肠易激综合征药物的药代动力学考虑因素：有什么新进展？

Expert opinion on drug metabolism & toxicology Pub Date : 2024-04-26 DOI: 10.1080/17425255.2024.2348488

S. Mozaffari, S. Nikfar, Mohammad Abdollahi

{"title":"Pharmacokinetic considerations for drugs that treat diarrhea-predominant irritable bowel syndrome: what's new?","authors":"S. Mozaffari, S. Nikfar, Mohammad Abdollahi","doi":"10.1080/17425255.2024.2348488","DOIUrl":"https://doi.org/10.1080/17425255.2024.2348488","url":null,"abstract":"INTRODUCTION\u0000Irritable bowel syndrome (IBS), which presents a significant healthcare and socioeconomic burden, is currently one of the main issues in the field of therapy. Hence, it is imperative to tackle this matter by evaluating the safety and efficacy of the available treatments and determining the ideal approach for each patient.\u0000\u0000\u0000AREAS COVERED\u0000We reviewed the pharmacokinetics characteristics and safety of pharmacologic interventions administered in diarrhea-predominant IBS (IBS-D) patients. PubMed, Google Scholar and the USFDA databases were searched up to November 2023 to identify and include all updated information on eluxadoline, alosetron, and rifaximin.\u0000\u0000\u0000EXPERT OPINION\u0000The most effective way to treat IBS-D is to focus on managing the most common and troublesome symptoms. However, healthcare providers face a challenge when it comes to identifying the right treatment for each patient, and the root cause of this is the diversity of the IBS-D population. Studies have shown that there are differences in how men and women metabolize drugs, which may lead to gender-specific adverse reactions. Women tend to have higher drug concentrations in their bloodstream and take longer to eliminate them. Therefore, healthcare providers may need to reduce the dosage for female patients to address this gender-specific issue. Integrating IBS care into sustainable development efforts can indirectly contribute to achieving SDGs and promote health and well-being for all.","PeriodicalId":94005,"journal":{"name":"Expert opinion on drug metabolism & toxicology","volume":"30 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140651973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical pharmacokinetics and pharmacodynamics of topical non-biological therapies for psoriasis patients. 银屑病患者外用非生物疗法的临床药代动力学和药效学。

Expert opinion on drug metabolism & toxicology Pub Date : 2024-04-01 Epub Date: 2024-04-02 DOI: 10.1080/17425255.2024.2337749

Angela Lo, Jonathan D Greenzaid, Hannah Y Gantz, Kamran Chodri, Steven R Feldman

{"title":"Clinical pharmacokinetics and pharmacodynamics of topical non-biological therapies for psoriasis patients.","authors":"Angela Lo, Jonathan D Greenzaid, Hannah Y Gantz, Kamran Chodri, Steven R Feldman","doi":"10.1080/17425255.2024.2337749","DOIUrl":"10.1080/17425255.2024.2337749","url":null,"abstract":"Introduction: Psoriasis is a chronic inflammatory cutaneous disease that causes patients psychosocial distress. Topical therapies are utilized for mild-to-moderate disease and for more severe disease in conjunction with systemic therapies. Topical corticosteroids are a cornerstone of treatment for psoriasis, but long-term use can cause stria and cutaneous atrophy and as well as systemic side effects such as topical steroid withdrawal. Non-steroidal topical therapies tend to be safer than topical corticosteroids for long-term use.Areas covered: We conducted a literature review on the pharmacokinetic (PK) and pharmacodynamic (PD) properties of topical therapies for psoriasis. We discuss how the PK and PD characteristics of these therapies inform clinicians on efficacy and toxicity when prescribing for patients.Expert opinion: Topical corticosteroids, used intermittently, are very safe and effective. Long-term, continuous use of topical corticosteroids can cause systemic side effects. Several generic and newly approved non-steroidal options are available, but no head-to-head studies compare the effectiveness of the generics (vitamin D analogs, tacrolimus, pimecrolimus) against the newer therapies (roflumilast, tapinarof). Patients often do not respond to topical therapies due to poor adherence to treatment regimens. For patients resistant to topical treatment, phototherapy or systemic therapy may be an option.","PeriodicalId":94005,"journal":{"name":"Expert opinion on drug metabolism & toxicology","volume":" ","pages":"235-248"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140327513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Risk factors associated with high-dose methotrexate induced toxicities. 与大剂量甲氨蝶呤引起的毒性相关的风险因素。

Expert opinion on drug metabolism & toxicology Pub Date : 2024-04-01 Epub Date: 2024-03-19 DOI: 10.1080/17425255.2024.2332366

Wenshu Li, Jiayi Mo, Zhilin Yang, Zhigang Zhao, Shenghui Mei

{"title":"Risk factors associated with high-dose methotrexate induced toxicities.","authors":"Wenshu Li, Jiayi Mo, Zhilin Yang, Zhigang Zhao, Shenghui Mei","doi":"10.1080/17425255.2024.2332366","DOIUrl":"10.1080/17425255.2024.2332366","url":null,"abstract":"Introduction: High-dose methotrexate (HDMTX) therapy poses challenges in various neoplasms due to individualized pharmacokinetics and associated adverse effects. Our purpose is to identify early risk factors associated with HDMTX-induced toxicities, paving the way for personalized treatment.Areas covered: A systematic review of PubMed and Cochrane databases was conducted for articles from inception to July 2023. Eligible studies included reviews, clinical trials, and real-world analyses. Irrelevant studies were excluded, and manual searches and citation reviews were performed. Factors such as MTX exposure, drug interactions, demographics, serum albumin, urine pH, serum calcium, and genetic polymorphisms affecting MTX transport (e.g. SLCO1B1), intracellular folate metabolism (MTHFR), cell development (ARID5B), metabolic pathways (UGT1A1, PNPLA3), as well as epigenetics were identified.Expert opinion: This comprehensive review aids researchers and clinicians in early identification of HDMTX toxicity risk factors. By understanding the multifaceted risk factors associated with hematologic malignancies, personalized treatment approaches can be tailored to optimize therapeutic outcomes.","PeriodicalId":94005,"journal":{"name":"Expert opinion on drug metabolism & toxicology","volume":" ","pages":"263-274"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140159835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Metabolic and toxicological considerations of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma. 治疗慢性淋巴细胞白血病/小淋巴细胞淋巴瘤的布鲁顿酪氨酸激酶抑制剂的代谢和毒理学考虑。

Expert opinion on drug metabolism & toxicology Pub Date : 2024-04-01 Epub Date: 2024-03-25 DOI: 10.1080/17425255.2024.2334322

Anna Wolska-Washer, Paweł Robak, Magdalena Witkowska, Tadeusz Robak

{"title":"Metabolic and toxicological considerations of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma.","authors":"Anna Wolska-Washer, Paweł Robak, Magdalena Witkowska, Tadeusz Robak","doi":"10.1080/17425255.2024.2334322","DOIUrl":"10.1080/17425255.2024.2334322","url":null,"abstract":"Introduction: Bruton tyrosine kinase inhibitors (BTKi) have been used for the management of human diseases since the approval of the first-in class agent, ibrutinib, by the Food and Drug Administration in 2013 for the treatment of patients with mantle cell lymphoma (MCL). Ibrutinib is a covalent inhibitor along with second-class BTKis: acalabrutinib and zanubrutinib. These well-tolerated agents have transformed the treatment landscape of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). A new class of these inhibitors, non-covalent, might become an answer to the emerging resistance by avoiding the sustained contact with the kinase binding domain.Areas covered: This article examines the chemical composition, mechanism of action, metabolic characteristics, and potential toxicity of inhibitors targeting Bruton tyrosine kinase. A comprehensive search was conducted across English-language articles in PubMed, Web of Science, and Google Scholar.Expert opinion: Bruton tyrosine kinase inhibitors have greatly enhanced the armamentarium against lymphoid malignancies including CLL/SLL. Their future lies in the choice of appropriate patients who will benefit from the treatment without significant adverse reaction. Combination chemotherapy-free fixed-duration regimens with targeted molecules will allow for MRD-driven approach in patients with CLL/SLL in the near future.","PeriodicalId":94005,"journal":{"name":"Expert opinion on drug metabolism & toxicology","volume":" ","pages":"207-224"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140186736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Metabolism, toxicity and management of fruquintinib: a novel drug for metastatic colorectal cancer. 治疗转移性结直肠癌的新药 fruquintinib 的代谢、毒性和管理。

Expert opinion on drug metabolism & toxicology Pub Date : 2024-04-01 Epub Date: 2024-03-20 DOI: 10.1080/17425255.2024.2332364

Kanchi Patell, Veronica Lee Mears, Michael H Storandt, Amit Mahipal

{"title":"Metabolism, toxicity and management of fruquintinib: a novel drug for metastatic colorectal cancer.","authors":"Kanchi Patell, Veronica Lee Mears, Michael H Storandt, Amit Mahipal","doi":"10.1080/17425255.2024.2332364","DOIUrl":"10.1080/17425255.2024.2332364","url":null,"abstract":"Introduction: Colorectal cancer (CRC) is the third most diagnosed cancer globally and despite therapeutic strides, the prognosis for patients with metastatic disease (mCRC) remains poor. Fruquintinib is an oral vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI) targeting VEGFR -1, -2, and -3, and has recently received approval by the U.S. Food and Drug Administration for treatment of mCRC refractory to standard chemotherapy, anti-VEGF therapy, and anti-epidermal growth factor receptor (EGFR) therapy.Areas covered: This article provides an overview of the pre-clinical data, pharmacokinetics, clinical efficacy, and safety profile of fruquintinib, as well as the management of clinical toxicities associated with fruquintinib.Expert opinion: Fruquintinib is a valuable additional treatment option for patients with refractory mCRC. The pivotal role of vigilant toxicity management cannot be understated. While fruquintinib offers a convenient and overall, well-tolerated treatment option, ongoing research is essential to determine its efficacy in different patient subsets, evaluate it in combination with chemotherapy and immunotherapy, and determine its role in earlier lines of therapy.","PeriodicalId":94005,"journal":{"name":"Expert opinion on drug metabolism & toxicology","volume":" ","pages":"197-205"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140144894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0